Meet
Massey Whorley

Massey Whorley provides clients with data-driven policy analysis using his quantitative skills, modeling expertise, and knowledge of public health insurance programs.

He applies his deep background in Medicaid, the Children's Health Insurance Program, the exchanges, and Medicare to help clients answer difficult questions. Massey models the impact of proposed federal changes and exogenous shocks on different business lines and the overall healthcare market. In particular, he has assisted clients with understanding how COVID-19, the associated economic downturn, and the subsequent federal response affect their business.

Prior to joining Avalere, Massey served in the administrations of former Governor Terry McAuliffe and Governor Ralph Northam, where he worked on a variety of healthcare-related issues including Medicaid expansion. He also has non-profit experience working for the Commonwealth Institute for Fiscal Analysis and experience as a legislative analyst for Virginia’s Joint Legislative Audit and Review Commission.

Massey has an MPP and a BA in public policy from the College of William and Mary.

Authored Content


Avalere analysis finds that when generics in Part D are placed on the preferred brand tier some patients pay the full cost for their drugs.

While access to insurance has increased for millions, mid-year plan switching can have unforeseen consequences for patients.

New Avalere analysis finds that lowering the Medicare eligibility age from 65 to 60 could expand access to Medicare coverage for an additional 24.5 million individuals, but Medicare premiums may be less affordable in some cases than subsidized exchange coverage.

Avalere analysis finds that Congress's healthcare reforms under the COVID-19 relief bill could expand exchange coverage subsidies for up to 18.3 million individuals.

Join Avalere’s panel of market access and policy experts to learn about the shifting insurance coverage landscape and how these trends impact manufacturers, payers, policymakers, and providers.

New Avalere analysis finds that the the Most Favored Nation (MFN) Model would have a significant negative impact on Medicare providers that furnish Part B drugs—especially in oncology and rheumatology—and those in rural areas.

Tune into another episode of Start Your Day with Avalere. In this segment, experts from Avalere’s Policy practice discuss the Most Favored Nation (MFN) drug pricing model, how it works, and the implications for stakeholders.

Compared to other drivers of state budget pressures during the COVID-19 pandemic—including higher Medicaid program enrollment due to increased unemployment and lower state tax revenues as a result of economic shutdowns—the relative financial impact of COVID-19 therapeutics on state Medicaid budgets will likely be minimal.

On September 13, the Trump Administration released the much-anticipated “Most Favored Nation” (MFN) Executive Order (EO), calling for models that would cap the price Medicare pays for select Part B and D drugs. The President’s EO underscores the administration’s continued focus on reducing prescription drug price disparities between the US and other developed countries.

New analysis of trade data finds that 54% of API, in dollars, used in domestically consumed medicines came from the US in 2019.

An analysis of CMS’s Hierarchical Condition Category (HCC) model shows that fully dual-eligible beneficiaries have the highest risk scores.

Avalere analysis finds that in the top 25 US counties with highest number of COVID-19 diagnoses, two-thirds of Medicare beneficiaries have 1 or more high-risk medical conditions.